Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$602K Buy
2,390
+6
+0.3% +$1.29K 0.28% 72
2026
Q1
$519K Hold
2,384
0.27% 78
2025
Q4
$529K Sell
2,384
-60
-2% -$13.7K 0.27% 75
2025
Q3
$566K Sell
2,444
-92
-4% -$18.7K 0.32% 67
2025
Q2
$471K Hold
2,536
0.29% 69
2025
Q1
$531K Sell
2,536
-29
-1% -$5.64K 0.36% 60
2024
Q4
$456K Sell
2,565
-319
-11% -$58.6K 0.3% 68
2024
Q3
$570K Buy
2,884
+48
+2% +$8.96K 0.39% 63
2024
Q2
$486K Buy
2,836
+60
+2% +$9.94K 0.37% 62
2024
Q1
$505K Sell
2,776
-48
-2% -$8.27K 0.42% 57
2023
Q4
$438K Buy
+2,824
New +$412K 0.41% 60

Other funds holding ABBV

Omni 360 Wealth's ABBV Position: Q2 2026 in Review

Omni 360 Wealth increased its AbbVie (ABBV) stake by 0.25% in Q2 2026, buying an estimated $1.29K and bringing the position to 2,390 shares worth $602K. The position accounts for 0.28% of the portfolio, ranked #72.

Omni 360 Wealth first reported a position in ABBV in Q4 2023 and has held it in 11 quarters since. 4,194 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Omni 360 Wealth held 2,390 shares of AbbVie worth $602K as of Q2 2026.
  • Omni 360 Wealth bought 6 AbbVie shares in Q2 2026, an estimated $1.29K.
  • AbbVie made up 0.28% of Omni 360 Wealth's portfolio in Q2 2026, its #72 holding.
  • Omni 360 Wealth first reported a position in AbbVie in Q4 2023 and has held it in 11 quarters since.
  • 4,194 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Omni 360 Wealth's 13F filing for Q2 2026, filed 13 Jul 2026.